Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06681051

Effectiveness and Safety of OSTENIL® TENDON in the Treatment of Pain and Restricted Mobility in Tendon Disorders

PMCF study to further substantiate the effectiveness and safety of OSTENIL® TENDON in the overall as well as indication-specific treatment of pain and restricted mobility in four different tendon disorders (patella tendon, peroneal tendon, medial epicondylus humeri and iliotibial band) in a real-life clinical setting when used according to the instructions for use.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Tendinopathy Muscular Diseases Musculoskeletal Diseases Tendon Injuries Wounds and Injuries

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Orthopädische Gemeinschaftspraxis ÜBAG, Berlin, State of Berlin, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged between 18 and 99 years
  • Diagnosis of symptomatic tendinopathy (patella tendon, peroneal tendon, medial epicondylus humeri or iliotibial band)
  • Physician's recommendation to use OSTENIL® TENDON prior to recruitment
  • Signed informed consent

Exclusion criteria

  • Presence of any contra-indication or precautionary condition listed in the instructions for use, i.e.,
  • Ascertained hypersensitivity to any of the OSTENIL® TENDON constituents
  • Known pregnancy or breast feeding
  • Acute trauma
  • Use of the following treatments (the given time intervals refer to the date of inclusion):
  • Local* OSTENIL® TENDON or other hyaluronic acid (HA) treatment within the last 6 months
  • Local* platelet-rich plasma (PRP) treatment within the last 3 months
  • Local* corticosteroid treatment (without time restriction)
  • Local* extracorporeal shock wave therapy (ESWT) within the last 4 weeks
  • Local* phytotherapy (e.g., Traumeel®) within the last 4 weeks
  • Local* surgical intervention (without time restriction)
  • Systemic corticosteroid treatment within the last 4 weeks
  • Repeated use of non-steroidal anti-inflammatory drugs (NSAID) and/or other analgesics within the last week
  • Physiotherapy (therapeutic exercises and physical therapy), ortheses, transcutaneous electrical nerve stimulation (TENS) or acupuncture within the last week
  • Diagnosis of chronic inflammatory disease (e.g. rheumatoid arthritis, Bechterew disease, Crohn's disease, etc.) prior to inclusion
  • Participation in a clinical investigation within the last 6 months
  • Vulnerable patient (individual who is unable to fully understand all aspects of the study that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response [including persons needing legally designated representatives, illiterate persons or persons with insufficient knowledge of local language])

(* local refers to the treatment of the study-relevant tendon)

Treatment and study plan

OSTENIL® TENDON

Device

OSTENIL® TENDON is a CE-certified viscoelastic solution intended for peritendinous or intrasheath injection, containing 2 % sodium hyaluronate from fermentation.

Primary outcomes

  1. Change of pain intensity 3 months after end of treatment compared to baseline (visual analogue scale)

    Time frame: Baseline compared to week 12 after the end of treatment.

    Evaluation of pain intensity by the patient on a 100 mm visual analogue scale. 100 mm equals the worst pain.

Secondary outcomes

  1. Change of Upper -/ Lower Extremity Functional Scale compared to baseline

    Time frame: Baseline compared to week 1 as well as weeks 4, 12 and 24 after the end of treatment.

    Indication specific patient questionnaire to assess effectiveness of treatment on a 5-point Likert scale (range: 0 = extreme difficulty to perform activity to 4 = no difficulty).

  2. Change of pain intensity compared to baseline (visual analogue scale)

    Time frame: Baseline compared to week 1 as well as weeks 4 and 24 after the end of treatment.

    Evaluation of pain intensity by the patient on a 100 mm visual analogue scale. 100 mm equals the worst pain.

  3. Change of patient-reported outcome measures (PROM)

    Time frame: Baseline (except satifaction with treatment), week 1 and weeks 4, 12 and 24 after the end of treatment.

    Patient questionnaire to assess the following aspects (100 mm visual analogue scale; 100 mm equals a worse outcome): pain, global and tendon-associated quality of life, daily activities, clinical global impression, mobility and satisfaction with treatment (note: not assessed at baseline)

  4. Change of investigator-reported outcome measures

    Time frame: Baseline (except satisfaction with treatment), week 1 and weeks 4, 12 and 24 after the end of treatment.

    Investigator inquiry to record the perception of the physician of the following aspects (100 mm visual analogue scale; 100 mm equals a worse outcome):

    clinical global impression regarding the clinical severity of the tendinopathy and satisfaction with the treatment (note: not assessed at baseline)

  5. Degree of tendinopathy

    Time frame: Baseline, week 1 and weeks 4, 12 and 24 after the end of treatment

    Evaluation of tendinopathy symptoms by the patient by rating tendon pain in the context of a patient-defined task that usually elicits pain (4 stages; 4 equals a worse outcome)

  6. Incidence of Adverse Events with (possible/probable) causal relationship with the device or application procedure

    Time frame: Up to week 24 after the end of treatment.

  7. Incidence of Serious Adverse Events with (possible/probable) causal relationship with the device or application procedure

    Time frame: Up to week 24 after the end of treatment.

  8. Incidence of (Presumably) serious incidents

    Time frame: Up to week 24 after the end of treatment.

  9. Incidence of Device Deficiencies

    Time frame: Up to week 24 after the end of treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Raphaela Geiger

CONTACT

[email protected]

+49 89-461483-27

Veronika Mussack, Dr.

CONTACT

[email protected]

+49 89-461483-43

Sponsors and collaborators

Lead sponsor

TRB Chemedica AG

Industry

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Nov 8, 2024
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.